Adlai Nortye Group Ltd. — Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual Form 20-F, not a standalone 2023 fourth-quarter report; quarterly results are not separately presented. The company is a Cayman Islands holding company with operating subsidiaries primarily in mainland China and the United States. Its ADSs, each representing three Class A ordinary shares, began trading on Nasdaq under “ANL” on September 29, 2023. Financial statements are prepared under IFRS.
Business context
Adlai Nortye is a clinical-stage biotechnology company focused on oncology therapies and combination immunotherapy. Its pipeline comprised three clinical-stage candidates—AN2025, AN0025 and AN4005—and three preclinical programs as of December 31, 2023. No drug candidate had received marketing approval, and the company had not generated product-sales revenue.
- AN2025/buparlisib: Global Phase III trial in combination with paclitaxel for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 therapy. Enrollment of 487 patients at more than 180 sites was completed in November 2023.
- AN0025/palupiprant: Phase Ib combination studies with pembrolizumab and chemoradiotherapy, including studies in solid tumors, esophageal cancer and rectal cancer.
- AN4005: Internally discovered oral small-molecule PD-L1 inhibitor in Phase I trials in the United States and China.
- Other programs: AN8025, AN1025 and AN9025 remained preclinical; management anticipated filing an IND for AN8025 in the first half of 2025.
Key financial metrics
| US$ in thousands, except per-share data | 2022 | 2023 | Change |
|---|---|---|---|
| Revenue | — | 5,000 | New revenue |
| Administrative expenses | 13,039 | 15,289 | +17.3% |
| Research and development expenses | 54,490 | 58,152 | +6.7% |
| Total operating loss | (67,270) | (67,551) | Broadly stable |
| Fair-value loss/(gain) on financial liabilities at FVTPL | 7,195 gain | (39,171) loss | Material adverse swing |
| Loss before tax | (58,790) | (104,228) | Loss increased |
| Net loss | (58,790) | (104,871) | Loss increased |
| Basic loss per share | $(2.31) | $(2.42) | More negative |
| Net cash used in operating activities | (43,223) | (56,652) | Higher cash burn |
| Cash and cash equivalents at year-end | 42,758 | 91,492 | +114.0% |
| Interest-bearing bank borrowings | 4,307 | 30,357 | Higher debt |
| Net current assets | (246,348) | 50,878 | Improved |
| Total equity | (241,293) | 79,403 | Improved |
2023 revenue consisted entirely of a US$5.0 million option grant fee from Nippon Kayaku for an exclusive option relating to AN2025 in Japan. It was recognized at a point in time, with no remaining performance obligation. The filing does not report recurring product revenue or a meaningful operating margin; the company remained pre-commercial and loss-making.
Cash flow was supported by US$116.2 million of financing inflows, primarily the September 2023 IPO and related financing. IPO net proceeds were approximately US$87.5 million; US$10.8 million had been used by December 31, 2023, leaving US$76.7 million unused at that date. Investing cash outflow was US$11.0 million, including purchases of US$31.8 million of investments at amortized cost.
Material changes versus 2022
- Revenue increased from zero to US$5.0 million, but the increase reflected a one-time option fee rather than product sales.
- R&D spending rose as clinical programs advanced, particularly CRO service costs.
- Administrative expenses increased primarily because of IPO-related professional fees.
- The company recorded a US$39.2 million fair-value loss on preferred-share and related financial liabilities in 2023, compared with a US$7.2 million fair-value gain in 2022. The 2023 loss was primarily associated with increased equity valuation before the liabilities converted into ordinary shares at the IPO.
- Preferred-share liabilities of US$290.4 million at December 31, 2022 converted into ordinary shares upon the IPO and were zero at December 31, 2023. This conversion drove the change from a 2022 net-liability position to positive equity.
- Operating cash burn increased from US$43.2 million to US$56.7 million. Cash nevertheless increased to US$91.5 million because of IPO and other financing proceeds.
- Bank borrowings increased to US$30.4 million at year-end, with substantially all borrowings classified as current and maturities concentrated in 2024.
Guidance, outlook, commentary and risks
- Management expected cash and cash equivalents, short-term investments and IPO/private-placement proceeds to fund operations for at least 12 months from the financial-statement issuance date. Management also acknowledged that additional financing will likely be required as clinical development and commercialization activities continue.
- Management expected to submit an NDA for AN2025 to the FDA in the first half of 2025, provided the overall-survival readout supports submission, followed by potential applications to China, Europe, Japan and other jurisdictions.
- Management expected top-line or dose-finding information for AN0025, the AN2025/AN0025/atezolizumab combination and AN4005 in the first half of 2024. These are forward-looking expectations and are not guarantees of successful development or approval.
- The filing identifies significant clinical, regulatory, manufacturing, intellectual-property, third-party collaboration, patient-enrollment, adverse-event and commercialization risks. None of the pipeline candidates had been approved for sale.
- The company relies on third-party CROs and CMOs and has no commercial sales or marketing infrastructure. Failure of trials, manufacturing arrangements or regulatory submissions could materially delay revenue generation.
- PRC regulatory, foreign-exchange, data-security and cross-border capital-transfer restrictions may limit the ability to move cash from mainland China subsidiaries to the offshore holding company.
- The company reported that disclosure controls and procedures were not effective as of December 31, 2023. Material weaknesses included inadequate segregation of duties and risk assessment, limited IFRS and tax expertise, and insufficient written accounting and SEC-reporting policies. Management reported improvement but had not established that the weaknesses were fully remediated.
- The company is a controlled company with a dual-class structure. Class B shares carry 15 votes per share, and founder Yang Lu controlled approximately 73.1% of aggregate voting power as of the filing date.
- The company reported no material pending legal or administrative proceeding, but disclosed broad exposure to litigation, product liability, regulatory enforcement, cybersecurity and intellectual-property risks.
Important facts for investors to verify
- Whether the AN2025 Phase III trial achieves its overall-survival endpoint and whether the FDA accepts and approves a 2025 NDA submission.
- Current cash, short-term investments, debt maturities and quarterly operating cash burn after December 31, 2023; the filing does not provide a standalone 2023 fourth-quarter cash-burn figure.
- Whether the company can fund operations without substantial dilution, additional debt or unfavorable licensing transactions.
- Status of AN0025 and AN4005 clinical readouts, recommended Phase II doses and any resulting regulatory plans.
- Progress in remediating material weaknesses in internal control over financial reporting and the effectiveness of disclosure controls.
- Terms and repayment status of 2024 bank facilities, including guarantees by Yang Lu and PRC subsidiary guarantees.
- Whether Nippon Kayaku exercises its AN2025 Japan option; as of the filing date it had not exercised the option, and the potential milestone and royalty economics are contingent on future execution.
- Potential dilution from approximately 9.96 million outstanding share awards at December 31, 2023, compared with 110.7 million ordinary shares outstanding as of that date.
- Ongoing exposure to PRC regulatory and foreign-exchange restrictions, HFCAA/PCAOB developments, currency movements and the company’s PFIC status for U.S. tax purposes.